Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PRO-156
- Development stage
- Unknown
- Lead developer
- Laboratorios Sophia
- Modality
- Peptides
- Administration
- Ophthalmic (topical To Eye)
01
Overview
PRO-156 is a synthetic peptide therapeutic agent under investigation primarily for ophthalmic use. It has been studied as an ophthalmic solution in a Phase 1 clinical trial to assess its safety and tolerability when administered over the ocular surface of healthy volunteers. The drug is being researched for potential applications in treating various medical conditions, including autoimmune disorders, but its primary documented development is for ophthalmological indications. The mechanism of action and specific molecular targets have not been publicly disclosed[1][2].
Beyond the preview
Go deeper on PRO-156.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PRO-156.